Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Pipeline Review, H1 2016 - Product Image

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Pipeline Review, H1 2016

  • ID: 3788886
  • Report
  • 68 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Kringle Pharma, Inc.
  • Ohr Pharmaceutical Inc.
  • Ribomic Inc.
  • MORE
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Pipeline Review, H1 2016

Summary

‘Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Pipeline Review, H1 2016’, provides in depth analysis on Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF)
- The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Kringle Pharma, Inc.
  • Ohr Pharmaceutical Inc.
  • Ribomic Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Overview

Therapeutics Development

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Stage of Development

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Therapy Area

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Indication

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Companies

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Universities/Institutes

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd.

Kringle Pharma, Inc.

Momenta Pharmaceuticals, Inc.

Ohr Pharmaceutical Inc.

Progen Pharmaceuticals Limited

Ribomic Inc.

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Drug Profiles

Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-400P - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GAL-F2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

necuparanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PG-545 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit FGF-2 for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

squalamine lactate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-764 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Dormant Projects

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Discontinued Products

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Featured News & Press Releases

Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO

May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting

May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee

Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA

Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program

Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program

Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting

Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology

Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion

Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer

May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting

May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference

Apr 30, 2015: Ohr Pharmaceutical to Present at the 2015 Association for Research in Vision and Ophthalmology Conference in Denver, CO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 68List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Kringle Pharma, Inc., H1 2016

Pipeline by Momenta Pharmaceuticals, Inc., H1 2016

Pipeline by Ohr Pharmaceutical Inc., H1 2016

Pipeline by Progen Pharmaceuticals Limited, H1 2016

Pipeline by Ribomic Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016 55List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Kringle Pharma, Inc.
  • Ohr Pharmaceutical Inc.
  • Ribomic Inc.
  • MORE
According to our recently published report 'Fibroblast Growth Factor 2 – Pipeline Review, H1 2016'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

The report 'Fibroblast Growth Factor 2 – Pipeline Review, H1 2016' outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
F. Hoffmann-La Roche Ltd.
Kringle Pharma, Inc.
Momenta Pharmaceuticals, Inc.
Ohr Pharmaceutical Inc.
Progen Pharmaceuticals Limited
Ribomic Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll